AR057810A1 - Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica - Google Patents

Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica

Info

Publication number
AR057810A1
AR057810A1 ARP060103981A ARP060103981A AR057810A1 AR 057810 A1 AR057810 A1 AR 057810A1 AR P060103981 A ARP060103981 A AR P060103981A AR P060103981 A ARP060103981 A AR P060103981A AR 057810 A1 AR057810 A1 AR 057810A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
alkoxy
piperazinyl
Prior art date
Application number
ARP060103981A
Other languages
English (en)
Inventor
Nicholas A Meanwell
Robert G Gentles
Min Ding
John A Bender
John F Kadow
Piyasena Hewawasam
Thomas W Hudyma
Xiaofan Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR057810A1 publication Critical patent/AR057810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Los compuestos de la formula (1), sales farmacéuticamente aceptables del mismo y composiciones. Los compuestos tienen actividad contra el virus de hepatitis C (VHC) y son utiles en el tratamiento de aquellos infectados con VHC. Reivindicacion 1: Un compuesto de la formula (1), en donde: R1 es CO2R5 o CONR6R7; R2 es hidroxi, alcoxi C1-6, NR8R9, o R3 es hidrogeno, halo, alquilo C1-6, o alcoxi C1-6; R4 es cicloalquilo C5-7; R5 es hidrogeno o alquilo; R6 es hidrogeno, alquilo C1-6, cicloalquilo C3- 7, alcoxi C1-6, o SO2R10; R7 es hidrogeno, alquilo C1-6, o cicloalquilo C3-7; R8 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, hidroxialquilo C1-6, alcoxiC1-6-alquiloC1-6, aminoalquilo C1-6, alquilaminoC1-6-alquiloC1-6, diquilaminoC1-6-alquilo C1- 6, R9 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, hidroxialquilo C1-6, alcoxiC1-6-alquiloC1-6, aminoalquilo C1-6, alquilaminoC1-6-alquiloC1-6, dialquilaminoC1-6-alquiloC1-6; o NR8 R9 al tomarse junto es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es sustituid o con 0-2 sustituyentes seleccionados de halo, hidroxi, alquilo C1-6, amino, alquilamino C1-6, dialquilamino C1-6, pirrolidinilo, piperidinilo, piperazinilo, N- (alquiloC1-6)piperazinilo, morfolinilo y tiomorfolinilo; y R10 es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, amino, alquilamino C1-6, dialquilamino C1-6, o R10 es pirrolidinilo, piperidinilo, piperazinilo, homomorfolinilo, homopiperidinilo, morfolinilo, o tiomorfolinilo, y es sustituido con 0-2 sustituyentes seleccionados de halo y alquilo c1-6; o una sal o solvato farmacéuticamente aceptable del mismo.
ARP060103981A 2005-09-12 2006-09-12 Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica AR057810A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71618705P 2005-09-12 2005-09-12
US80997906P 2006-06-01 2006-06-01
US11/507,731 US7399758B2 (en) 2005-09-12 2006-08-22 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Publications (1)

Publication Number Publication Date
AR057810A1 true AR057810A1 (es) 2007-12-19

Family

ID=37603284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103981A AR057810A1 (es) 2005-09-12 2006-09-12 Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica

Country Status (5)

Country Link
US (2) US7399758B2 (es)
AR (1) AR057810A1 (es)
PE (1) PE20070676A1 (es)
TW (1) TW200745035A (es)
WO (1) WO2007033032A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7795247B2 (en) 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2029606B1 (en) * 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
JP5211078B2 (ja) * 2007-03-13 2013-06-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2693533A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2375065T3 (es) * 2007-11-20 2012-02-24 Bristol-Myers Squibb Company Inhibidores de indilobenzazepina condensada con ciclopropilo de la ns5b del vhc.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2009080836A2 (en) 2007-12-24 2009-07-02 Tibotec Pharmaceuticals Ltd. Macrocyclic indoles as hepatitis c virus inhibitors
ES2437147T3 (es) 2008-02-04 2014-01-09 Idenix Pharmaceuticals, Inc. Inhibidores de serina proteasa macrocíclicos
MX2010010245A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
JP2011515484A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
JP2011517673A (ja) 2008-03-27 2011-06-16 ブリストル−マイヤーズ スクイブ カンパニー 芳香族ヘテロ環縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2385838A1 (en) 2009-01-07 2011-11-16 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CN103097356B (zh) 2010-06-24 2016-01-13 爱尔兰詹森科学公司 13-环己基-3-甲氧基-6-[甲基-(2-{2-[甲基-(氨磺酰基)-氨基]-乙氧基}-乙基)-氨基甲酰基]-7H-吲哚并-[2,1-a]-[2]-苯并氮杂*-10-羧酸的制备
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005293821B2 (en) 2004-10-13 2011-05-12 Merck Patent Gmbh N,N'-dithenylurea derivatives used in the form of kinase inhibitors
JP2008517987A (ja) 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としての四環式インドール誘導体
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Also Published As

Publication number Publication date
US20070184024A1 (en) 2007-08-09
PE20070676A1 (es) 2007-08-10
WO2007033032A1 (en) 2007-03-22
TW200745035A (en) 2007-12-16
US7485633B2 (en) 2009-02-03
US20070060565A1 (en) 2007-03-15
US7399758B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
JP2010521483A5 (es)
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
DE602005023015D1 (de) Indolderivate als viruzide
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO6180426A2 (es) Compuesto para el tratamiento de la hepatitis b
HRP20090627T1 (hr) Inhibitori hcv ns3 proteaze
AR049739A1 (es) Derivados de aril-piridina
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
HUP0402679A2 (hu) Pirrolidin- és piperidin-származékok mint NK1 antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
AR045180A1 (es) Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure